A chronic lymphocytic leukemia patient in a clinical trial for CD19 CAR T cell therapy (trial: NCT01029366) exhibited clonal CAR T cell expansion due to retroviral insertion disrupting the TET2 gene [11]. This evidence concerns the gene TET2 and B-cell chronic lymphocytic leukemia.